Cargando…

Treatment of Secondary Chorea: A Review of the Current Literature

BACKGROUND: Chorea consists of involuntary movements affecting the limbs, trunk, neck or face, that can move from one body part to another. Chorea is conceptualized as being “primary” when it is attributed to Huntington’s disease (HD) or other genetic etiologies, or “secondary” when it is related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Feinstein, Erin, Walker, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394219/
https://www.ncbi.nlm.nih.gov/pubmed/32775036
http://dx.doi.org/10.5334/tohm.351
_version_ 1783565194555817984
author Feinstein, Erin
Walker, Ruth
author_facet Feinstein, Erin
Walker, Ruth
author_sort Feinstein, Erin
collection PubMed
description BACKGROUND: Chorea consists of involuntary movements affecting the limbs, trunk, neck or face, that can move from one body part to another. Chorea is conceptualized as being “primary” when it is attributed to Huntington’s disease (HD) or other genetic etiologies, or “secondary” when it is related to infectious, pharmacologic, metabolic, autoimmune disorders, or paraneoplastic syndromes. The mainstay of the secondary chorea management is treating the underlying causative disorder; here we review the literature regarding secondary chorea. We also discuss the management of several non-HD genetic diseases in which chorea can be a feature, where metabolic targets may be amenable to intervention and chorea reduction. METHODS: A PubMed literature search was performed for articles relating to chorea and its medical and surgical management. We reviewed the articles and cross-references of pertinent articles to assess the current clinical practice, expert opinion, and evidence-based medicine to synthesize recommendations for the management of secondary chorea. RESULTS: There are very few double-blind randomized controlled trials assessing chorea treatments regardless of etiology. Most recommendations are based on small open-label studies, case reports, and expert opinion. DISCUSSION: Treatment of secondary chorea is currently based on expert opinion, clinical experience, and small case studies, with limited evidence-based medical data. When chorea is secondary to an underlying infection, medication, metabolic abnormality, autoimmune process, or paraneoplastic illness, the movements typically resolve following treatment of the underlying disease. Tardive dyskinesia is most rigorously studied secondary chorea with the best evidence-based medicine treatment guidelines recommending the use of pre-synaptic dopamine-depleting agents. Even though there is an insufficient pool of EBM, small clinical trials, case reports, and expert opinion are valuable for guiding treatment and improving the quality of life for patients with chorea. HIGHLIGHTS: There is a dearth of well-controlled studies regarding the treatment of chorea. Expert opinion and clinical experiences are fundamental in guiding chorea management and determining successful treatment. In general, secondary chorea improves with treating the underlying medical abnormality; treatments include antibiotics, antivirals, immunosuppression, dopamine depleting agents, chelation, and supportive care.
format Online
Article
Text
id pubmed-7394219
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-73942192020-08-07 Treatment of Secondary Chorea: A Review of the Current Literature Feinstein, Erin Walker, Ruth Tremor Other Hyperkinet Mov (N Y) Review BACKGROUND: Chorea consists of involuntary movements affecting the limbs, trunk, neck or face, that can move from one body part to another. Chorea is conceptualized as being “primary” when it is attributed to Huntington’s disease (HD) or other genetic etiologies, or “secondary” when it is related to infectious, pharmacologic, metabolic, autoimmune disorders, or paraneoplastic syndromes. The mainstay of the secondary chorea management is treating the underlying causative disorder; here we review the literature regarding secondary chorea. We also discuss the management of several non-HD genetic diseases in which chorea can be a feature, where metabolic targets may be amenable to intervention and chorea reduction. METHODS: A PubMed literature search was performed for articles relating to chorea and its medical and surgical management. We reviewed the articles and cross-references of pertinent articles to assess the current clinical practice, expert opinion, and evidence-based medicine to synthesize recommendations for the management of secondary chorea. RESULTS: There are very few double-blind randomized controlled trials assessing chorea treatments regardless of etiology. Most recommendations are based on small open-label studies, case reports, and expert opinion. DISCUSSION: Treatment of secondary chorea is currently based on expert opinion, clinical experience, and small case studies, with limited evidence-based medical data. When chorea is secondary to an underlying infection, medication, metabolic abnormality, autoimmune process, or paraneoplastic illness, the movements typically resolve following treatment of the underlying disease. Tardive dyskinesia is most rigorously studied secondary chorea with the best evidence-based medicine treatment guidelines recommending the use of pre-synaptic dopamine-depleting agents. Even though there is an insufficient pool of EBM, small clinical trials, case reports, and expert opinion are valuable for guiding treatment and improving the quality of life for patients with chorea. HIGHLIGHTS: There is a dearth of well-controlled studies regarding the treatment of chorea. Expert opinion and clinical experiences are fundamental in guiding chorea management and determining successful treatment. In general, secondary chorea improves with treating the underlying medical abnormality; treatments include antibiotics, antivirals, immunosuppression, dopamine depleting agents, chelation, and supportive care. Ubiquity Press 2020-07-16 /pmc/articles/PMC7394219/ /pubmed/32775036 http://dx.doi.org/10.5334/tohm.351 Text en Copyright: © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Feinstein, Erin
Walker, Ruth
Treatment of Secondary Chorea: A Review of the Current Literature
title Treatment of Secondary Chorea: A Review of the Current Literature
title_full Treatment of Secondary Chorea: A Review of the Current Literature
title_fullStr Treatment of Secondary Chorea: A Review of the Current Literature
title_full_unstemmed Treatment of Secondary Chorea: A Review of the Current Literature
title_short Treatment of Secondary Chorea: A Review of the Current Literature
title_sort treatment of secondary chorea: a review of the current literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394219/
https://www.ncbi.nlm.nih.gov/pubmed/32775036
http://dx.doi.org/10.5334/tohm.351
work_keys_str_mv AT feinsteinerin treatmentofsecondarychoreaareviewofthecurrentliterature
AT walkerruth treatmentofsecondarychoreaareviewofthecurrentliterature